Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 17/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973421 | 0.89 | RXFP1 (0.53) | RXFP1MAPTNPSR1P2RX1SMN1; SMN2 | |
| SCHEMBL19973422 | 0.89 | RXFP1 (0.53) | RXFP1MAPTNPSR1P2RX1SMN1; SMN2 | |
| SCHEMBL21189242 | 0.86 | TRPV1 (0.47) | PTGS1 | |
| SCHEMBL21189407 | 0.86 | CREBBP (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL21189185 | 0.85 | FADS1 (0.45) | P2RX1SMN1; SMN2 | |
| SCHEMBL21189485 | 0.85 | TP53 (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL21189206 | 0.85 | TP53 (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL21189262 | 0.85 | TP53 (0.42) | MAPTSMN1; SMN2 | |
| SCHEMBL21189350 | 0.84 | TRPV1 (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL21189267 | 0.83 | AKR1C3 (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | RXFP1 4469/4885MAPT 3165/4885NPSR1 4645/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | RXFP1 4469/4885MAPT 3165/4885NPSR1 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.